Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Jae Won Hong  (Hong JW) 6 Articles
Diabetes
Association between White Blood Cell Counts within Normal Range and Hemoglobin A1c in a Korean Population
Jae Won Hong, Jung Hyun Noh, Dong-Jun Kim
Endocrinol Metab. 2018;33(1):79-87.   Published online January 30, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.79
  • 4,840 View
  • 54 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

We examined whether white blood cell (WBC) count levels within normal range, could be associated with hemoglobin A1c (HbA1c) levels.

Methods

Among the 11,472 people (≥19 years of age) who participated in the 2011 to 2012 Korea National Health and Nutrition Examination, subjects with chronic disease or illness, including 807 patients with diabetes currently taking anti-diabetic medications and/or 1,149 subjects with WBC levels <4,000 or >10,000/µL were excluded.

Results

Overall, adjusted HbA1c levels increased across the WBC quartiles (5.55%±0.01%, 5.58%±0.01%, 5.60%±0.01%, and 5.65%±0.01%, P<0.001) after adjusting for confounding factors, such as age, gender, fasting plasma glucose, college graduation, smoking history, waist circumference, presence of hypertension, serum total cholesterol, serum triglyceride, and presence of anemia. The adjusted proportions (%) of HbA1c levels of ≥5.7%, ≥6.1%, and ≥6.5% showed significant increases across WBC quartiles (P<0.001, P=0.002, and P=0.022, respectively). Logistic regression analyses of WBC quartiles for the risk of HbA1c levels of ≥5.7%, ≥6.1%, and ≥6.5%, using the variables above as covariates, showed that the odds ratios of the fourth quartile of WBCs were 1.59 (95% confidence interval [CI], 1.35 to 1.89; P<0.001), 1.78 (95% CI, 1.31 to 2.42; P<0.001), and 2.03 (95% CI, 1.13 to 3.64; P=0.018), using the first quartile of WBCs as the reference.

Conclusion

HbA1c levels were positively associated with WBC levels within normal range in a general adult population.

Citations

Citations to this article as recorded by  
  • Vitamin D supplementation modulates glycated hemoglobin (HBA1c) in diabetes mellitus
    Asma Akhter, Sultan Alouffi, Uzma Shahab, Rihab Akasha, Mohd Fazal-Ur-Rehman, Mohamed E. Ghoniem, Naved Ahmad, Kirtanjot Kaur, Ramendra Pati Pandey, Ahmed Alshammari, Firoz Akhter, Saheem Ahmad
    Archives of Biochemistry and Biophysics.2024; 753: 109911.     CrossRef
  • Glucose indices as inflammatory markers in children with acute surgical abdomen: a cross-sectional study
    Hoda Atef Abdelsattar Ibrahim, Sherif Kaddah, Sara Mohamed Elkhateeb, Abeer Aboalazayem, Aya Ahmed Amin, Mahmoud Marei Marei
    Annals of Medicine.2023;[Epub]     CrossRef
  • Factors associated with relative muscle strength in patients with type 2 diabetes mellitus
    Chiao-Nan Chen, Ting-Chung Chen, Shiow-Chwen Tsai, Chii-Min Hwu
    Archives of Gerontology and Geriatrics.2021; 95: 104384.     CrossRef
  • Non-vascular contributing factors of diabetic foot ulcer severity in national referral hospital of Indonesia
    Em Yunir, Dicky L. Tahapary, Tri Juli Edi Tarigan, Dante Saksono Harbuwono, Yoga Dwi Oktavianda, Melly Kristanti, Eni Iswati, Angela Sarumpaet, Pradana Soewondo
    Journal of Diabetes & Metabolic Disorders.2021; 20(1): 805.     CrossRef
  • Association between Inflammatory Markers and Glycemic Control in Korean Diabetic Patients
    Min Kang, Seok-Joon Sohn
    Journal of Health Informatics and Statistics.2021; 46(3): 247.     CrossRef
  • Prediabetes Is Independently Associated with Subclinical Carotid Atherosclerosis: An Observational Study in a Non-Urban Mediterranean Population
    Maria Belén Vilanova, Josep Franch-Nadal, Mireia Falguera, Josep Ramon Marsal, Sílvia Canivell, Esther Rubinat, Neus Miró, Àngels Molló, Manel Mata-Cases, Mònica Gratacòs, Esmeralda Castelblanco, Dídac Mauricio
    Journal of Clinical Medicine.2020; 9(7): 2139.     CrossRef
Close layer
Adrenal gland
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
Youngki Lee, Cheol Ryong Ku, Eui-Hyun Kim, Jae Won Hong, Eun Jig Lee, Sun Ho Kim
Endocrinol Metab. 2014;29(3):280-292.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.280
  • 4,657 View
  • 57 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Cabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resistance, and the early characteristics of these patients remain unclear. We analyzed early indicators predicting long-term response to cabergoline.

Methods

We retrospectively reviewed the cases of 44 patients with macroprolactinomas who received cabergoline as first-line treatment; the patients were followed for a median of 16 months. The influence of various clinical parameters on outcomes was evaluated.

Results

Forty patients (90.9%) were treated medically and displayed tumor volume reduction (TVR) of 74.7%, a prolactin normalization (NP) rate of 81.8%, and a complete response (CR; TVR >50% with NP, without surgery) rate of 70.5%. Most patients (93.1%) with TVR ≥25% and NP at 3 months eventually achieved CR, whereas only 50% of patients with TVR ≥25% without NP and no patients with TVR <25% achieved CR. TVR at 3 months was strongly correlated with final TVR (R=0.785). Patients with large macroadenomas exhibited a low NP rate at 3 months, but eventually achieved TVR and NP rates similar to those of patients with smaller tumors. Surgery independently reduced the final dose of cabergoline (β=-1.181 mg/week), and two of four patients who underwent surgery were able to discontinue cabergoline.

Conclusion

Determining cabergoline response using TVR and NP 3 months after treatment is useful for predicting later outcomes. However, further cabergoline administration should be considered for patients with TVR >25% at 3 months without NP, particularly those with huge prolactinomas, because a delayed response may be achieved. As surgery can reduce the cabergoline dose necessary for successful disease control, it should be considered for cabergoline-resistant patients.

Citations

Citations to this article as recorded by  
  • Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
    Irena A. Ilovayskaya, Gulnar R. Vagapova
    Almanac of Clinical Medicine.2024; 51(7): 397.     CrossRef
  • Medical treatment of functional pituitary adenomas, trials and tribulations
    Cristina Capatina, Felicia Alexandra Hanzu, José Miguel Hinojosa-Amaya, Maria Fleseriu
    Journal of Neuro-Oncology.2024; 168(2): 197.     CrossRef
  • Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
    Stephan Petersenn, Maria Fleseriu, Felipe F. Casanueva, Andrea Giustina, Nienke Biermasz, Beverly M. K. Biller, Marcello Bronstein, Philippe Chanson, Hidenori Fukuoka, Monica Gadelha, Yona Greenman, Mark Gurnell, Ken K. Y. Ho, Jürgen Honegger, Adriana G.
    Nature Reviews Endocrinology.2023; 19(12): 722.     CrossRef
  • Outcome Measures for Medical and Surgical Treatment of Prolactinomas. Is the Role of Surgery Underestimated?
    Andrius Anuzis, Kevin O. Lillehei
    Journal of Neurological Surgery Part B: Skull Base.2023;[Epub]     CrossRef
  • Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
    Xiangming Cai, Junhao Zhu, Jin Yang, Chao Tang, Zixiang Cong, Chiyuan Ma
    Chinese Neurosurgical Journal.2022;[Epub]     CrossRef
  • Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors
    Renato Cozzi, Maria Rosaria Ambrosio, Roberto Attanasio, Claudia Battista, Alessandro Bozzao, Marco Caputo, Enrica Ciccarelli, Laura De Marinis, Ernesto De Menis, Marco Faustini Fustini, Franco Grimaldi, Andrea Lania, Giovanni Lasio, Francesco Logoluso, M
    European Journal of Endocrinology.2022; 186(3): P1.     CrossRef
  • Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma
    Kyungwon Kim, Yae Won Park, Daham Kim, Sung Soo Ahn, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Cheol Ryong Ku
    The Journal of Clinical Endocrinology & Metabolism.2021; 106(2): e615.     CrossRef
  • Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas
    Ji Yong Park, Wonsuk Choi, A Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Woo-Youl Jang, Shin Jung, Ho-Cheol Kang
    Pituitary.2021; 24(6): 955.     CrossRef
  • Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications
    Betina Biagetti, Rafael Simò
    International Journal of Molecular Sciences.2021; 22(20): 11247.     CrossRef
  • A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas
    Rakesh Mishra, SubhasK Konar, Adesh Shrivastava, Pradeep Chouksey, Sumit Raj, Amit Agrawal
    Indian Journal of Endocrinology and Metabolism.2021; 25(6): 493.     CrossRef
  • Predictors of dopamine agonist resistance in prolactinoma patients
    Elle Vermeulen, Jean D’Haens, Tadeusz Stadnik, David Unuane, Kurt Barbe, Vera Van Velthoven, Sven Gläsker
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • The Role of Dopamine Agonists in Pituitary Adenomas
    Erica A. Giraldi, Adriana G. Ioachimescu
    Endocrinology and Metabolism Clinics of North America.2020; 49(3): 453.     CrossRef
  • Prevalence of Thyroid Disease in Patients Surgically Treated for Pituitary Disease
    Daham Kim, Yongin Cho, Cheol Ryong Ku, Hyein Jung, Ju Hyung Moon, Eui Hyun Kim, Dong Yeob Shin, Sun Ho Kim, Eun Jig Lee
    Journal of Clinical Medicine.2019; 8(8): 1142.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer
Adrenal gland
Characteristics of Acromegaly in Korea with a Literature Review
Jae Won Hong, Cheol Ryong Ku, Sun Ho Kim, Eun Jig Lee
Endocrinol Metab. 2013;28(3):164-168.   Published online September 13, 2013
DOI: https://doi.org/10.3803/EnM.2013.28.3.164
  • 3,919 View
  • 54 Download
  • 12 Crossref
AbstractAbstract PDFPubReader   

Acromegaly is a slowly progressive disease caused by excessive growth hormone (GH), which is related to a GH secreting pituitary tumor in most cases. Herein, we describe the epidemiology, clinical characteristics, and treatment of acromegaly in Korea with a literature review. The average annual incidence of acromegaly in Korea was 3.9 cases per million people, which was within the range of previous Western studies. The primary treatment for acromegaly was also transsphenoidal adenomectomy, which accounted for 90.4% of patients whose primary therapeutic options were known. The overall surgical remission rates were 89%, 87%, 64%, 70%, and 50% for modified Hardy classification I, II, IIIA, IIIB, and IV, respectively. An updated and larger study regarding the treatment outcome of medical/radiotherapy in Korean acromegalic patients is needed.

Citations

Citations to this article as recorded by  
  • Risk of depression in patients with acromegaly in Korea (2006-2016): a nationwide population-based study
    Shinje Moon, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    European Journal of Endocrinology.2023; 189(3): 363.     CrossRef
  • Increased Risk of Hip Fracture in Patients with Acromegaly: A Nationwide Cohort Study in Korea
    Jiwon Kim, Namki Hong, Jimi Choi, Ju Hyung Moon, Eui Hyun Kim, Eun Jig Lee, Sin Gon Kim, Cheol Ryong Ku
    Endocrinology and Metabolism.2023; 38(6): 690.     CrossRef
  • Selective screening of patients with associated somatic diseases as a method of early detection of acromegaly
    M. B. Antsiferov, V. S. Pronin, T. M. Alekseeva, O. A. Ionova, E. Y. Martynova, Yu. E. Poteshkin, N. A. Chubrova, K. Y. Zherebchikova
    Problems of Endocrinology.2021; 67(1): 20.     CrossRef
  • Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
    Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee
    Endocrinology and Metabolism.2020; 35(2): 206.     CrossRef
  • Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study
    Xiaopeng Guo, Kailu Wang, Siyue Yu, Lu Gao, Zihao Wang, Huijuan Zhu, Bing Xing, Shuyang Zhang, Dong Dong
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Epidemiología de la acromegalia en Ecuador
    Enrique López Gavilanez, Kempis Guerrero Franco, Narcisa Solórzano Zambrano, Manuel Navarro Chávez, Camilo López Estrella, Luis Vaca Burbano, Eduardo Marriott Díaz
    Endocrinología y Nutrición.2016; 63(7): 333.     CrossRef
  • A magnetic resonance imaging‐based classification system for indication of trans‐sphenoidal hypophysectomy in canine pituitary‐dependent hypercortisolism
    A. Sato, T. Teshima, H. Ishino, Y. Harada, T. Yogo, N. Kanno, D. Hasegawa, Y. Hara
    Journal of Small Animal Practice.2016; 57(5): 240.     CrossRef
  • Epidemiology of acromegaly in Ecuador
    Enrique López Gavilanez, Kempis Guerrero Franco, Narcisa Solórzano Zambrano, Manuel Navarro Chávez, Camilo López Estrella, Luis Vaca Burbano, Eduardo Marriott Díaz
    Endocrinología y Nutrición (English Edition).2016; 63(7): 333.     CrossRef
  • An Association Study Between Gene Polymorphisms of Folic Acid Metabolism Enzymes and Biochemical and Hormonal Parameters in Acromegaly
    Aslı Tetik Vardarlı, Ayhan Zengi, Vildan Bozok Çetintaş, Muammer Karadeniz, Sadık Tamsel, Ali Şahin Küçükaslan, Timur Köse, Füsun Saygılı, Zuhal Eroglu
    Genetic Testing and Molecular Biomarkers.2015; 19(8): 431.     CrossRef
  • Diagnosis, treatment and clinical perspectives of acromegaly
    Ferdinand Roelfsema, Gerrit van den Berg
    Expert Review of Endocrinology & Metabolism.2015; 10(6): 619.     CrossRef
  • Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
    Sang Ouk Chin, Choon Hee Chung, Yoon-Sok Chung, Byung-Joon Kim, Hee Young Kim, In-Ju Kim, Jung Guk Kim, Min-Seon Kim, Seong-Yeon Kim, Eun Jig Lee, Ki Young Lee, Sung-Woon Kim
    BMJ Open.2015; 5(6): e006898.     CrossRef
  • Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
    Won-Young Lee
    Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Close layer
A Case of Latent Autoimmune Diabetes in Adults Developed after Surgical Cure of Growth Hormone Secreting Pituitary Tumor.
Wonjin Kim, Jung Ho Kim, Youngsook Kim, Ji Hye Huh, Su Jin Lee, Mi Sung Park, Eun Yeong Choe, Jeong Kyung Park, Myung Won Lee, Jae Won Hong, Byung Wan Lee, Eun Seok Kang, Bong Soo Cha, Eun Jig Lee, Hyun Chul Lee
Endocrinol Metab. 2012;27(4):318-322.   Published online December 20, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.4.318
  • 2,107 View
  • 32 Download
AbstractAbstract PDF
Acromegaly is generally caused by a benign growth hormone (GH)-secreting pituitary adenoma. It is characterized by a wide range of complications; cardiovascular, respiratory, bone and joint, and metabolic complications. Among them, impaired glucose tolerance and diabetes mellitus, due to GH-induced insulin resistance, has been reported in approximately 16-46% and 19-56%. They are usually improved following the treatment of acromegaly, surgical or medical therapy. We report a first case of 36-year-old man who was paradoxically diagnosed with GAD antibody positive latent autoimmune diabetes in adults (LADA) after the surgical cure of acromegaly.
Close layer
Secondary Pituitary Hyperplasia Induced by Hashimoto's Thyroiditis Related Hypothyroidism: A Case Report.
Kwang Joon Kim, Hyun min Kim, Obin Kwon, Eun Young Park, Yong ho Lee, Jae Won Hong, Jin Wi, Eun Jig Lee
J Korean Endocr Soc. 2010;25(1):72-77.   Published online March 1, 2010
DOI: https://doi.org/10.3803/jkes.2010.25.1.72
  • 2,062 View
  • 33 Download
  • 2 Crossref
AbstractAbstract PDF
Pituitary hyperplasia associated with untreated primary hypothyroidism in children is a rare condition. There are only a few reports on this condition in children, and especially when pituitary hyperplasia is accompanied with Hashimoto thyroiditis and growth arrest. Here, we describe an unusual association of pituitary hyperplasia with hypothyroidism and growth retardation, and this was all caused by Hashimoto thyroiditis. Hormonal testing showed a low thyroxine level and a high thyroid stimulating hormone level, elevated anti-thyroglobulin, low growth hormone levels and prepubertal levels of gonadotropins. A large intrasellar mass expanding beyond the sella turcica was detected on magnetic resonance imaging (MRI). Homogeneous contrast enhancement of mass highly suggested that it was a pituitary hyperplasia rather than a pituitary tumor. Therapy with L-thyroxine resulted in rapid improvement of the clinical signs, including renewed growth, normalization of the hormone levels and resolution of the pituitary hyperplasia on MRI within 90 days. In children, prolonged unrecognized primary hypothyroidism might be accompanied by growth deficiency and pubertal disharmony. Physicians must be aware of pituitary hyperplasia in these cases.

Citations

Citations to this article as recorded by  
  • Pituitary macroadenoma secondary to Hashimoto’s thyroiditis: inadvertent diagnosis in a pre-pubertal girl
    Deepanjan Bhattacharya, Rakesh Kumar, Jaivinder Yadav
    Tropical Doctor.2020; 50(3): 240.     CrossRef
  • Pituitary Hyperplasia Secondary to Hypothyroidism Caused by Hashimoto's Thyroiditis in a Female Adolescent
    Jeoung Suk Kim, Min Sun Kim, Sun Jun Kim, Gyung Ho Chung, Pyoung Han Hwang, Dae-Yeol Lee
    Journal of Korean Society of Pediatric Endocrinology.2011; 16(3): 185.     CrossRef
Close layer
A Case of Insulin Autoimmune Syndrome in a Patient with Partial Hypopituitarism.
Obin Kwon, Eun Young Park, Jin Young Yoon, Kwang Joon Kim, Yong ho Lee, Jae Won Hong, Eun Jig Lee, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha
J Korean Endocr Soc. 2009;24(4):281-286.   Published online December 1, 2009
DOI: https://doi.org/10.3803/jkes.2009.24.4.281
  • 1,801 View
  • 23 Download
AbstractAbstract PDF
Insulin autoimmune syndrome is one of the rare causes of hypoglycemia, and characterized by hyperinsulinemic hypoglycemia associated with high titer of antibodies to endogenous insulin. We report a case of insulin autoimmune syndrome in a 57-year-old woman, presenting with mental changes due to hypoglycemia. She had no history of diabetes or insulin administration. The serum C-peptide level was 4.69 ng/mL and the insulin concentration was 229.55 microU/mL, when fasting plasma glucose level was 32 mg/dL. The insulin-to-glucose ratio was 7.17, while there was no radiologic evidence of insulinoma. The insulin antibody level was over 100 microU/mL, resulting in the diagnosis of insulin autoimmune syndrome. Hormonal studies revealed partial hypopituitarism and a lack of glucagon-response to hypoglycemia. Hypoglycemia disappeared with replacement of prednisolone with levothyroxine therapy. Under secretion of growth hormone and of adrenocorticotropic hormone due to hypopituitarism were associated with insufficient counterregulation to hypoglycemia. One should keep in mind that insulin autoimmune syndrome or hypopituitarism is one cause of hypoglycemia in patients with no history of diabetes, and corticosteroid can be an effective treatment for both diseases.
Close layer

Endocrinol Metab : Endocrinology and Metabolism